Dilpacimab ELISA Kit

• Background :

  Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.

• Specifications :

  Dilpacimab

• Product Name Alternative :

  ABT-165, PR-1283233, CAS: 1791420-09-1

• Detection Method :

  Colorimetric

• Assay Type :

  Quantitative

• Sample Type :

  Plasma, Serum

• Detection Range :

  0.31-5 μg/mL

• Recovery :

  80-120%

• Sensitivity :

  0.156 μg/ml

• Shipping Conditions :

  2-8 °C

• Storage Conditions :

  The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

• Notes :

  For Research Use Only.